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Upon systemic bacterial infection, hematopoietic
stem and progenitor cells (HSPCs) migrate to the pe-
riphery in order to supply a sufficient number of
immune cells. Although pathogen-associatedmolec-
ular patterns reportedly mediate HSPC activation,
how HSPCs detect pathogen invasion in vivo re-
mains elusive. Bacteria use the second messenger
bis-(30-50)-cyclic dimeric guanosine monophosphate
(c-di-GMP) for a variety of activities. Here, we report
that c-di-GMP comprehensively regulated both
HSPCs and their niche cells through an innate im-
mune sensor, STING, thereby inducing entry into
the cell cycle and mobilization of HSPCs while
decreasing the number and repopulation capacity
of long-term hematopoietic stem cells. Furthermore,
we show that type I interferon acted as a downstream
target of c-di-GMP to inhibit HSPC expansion in the
spleen, while transforming growth factor-b was
required for c-di-GMP-dependent splenic HSPC
expansion. Our results define machinery underlying
the dynamic regulation of HSPCs and their niches
during bacterial infection through c-di-GMP/STING
signaling.INTRODUCTION
Hematopoietic stem cells (HSCs) have both self-renewal and
multiple differentiation capacities to replenish the entire hemato-
poietic system throughout the organismal lifespan (Orkin and
Zon, 2008). While HSCs remain quiescent in terms of the cell cy-cle at a steady state, they rapidly re-enter the cell cycle to
generate differentiated hematopoietic cells in a demand-driven
manner following exposure to various stimuli, including cytotoxic
agents, irradiation, and infectious stresses (Blanpain et al.,
2011). Upon systemic infection by external pathogens, periph-
eral immune cells are challenged and rapidly consumed,
requiring a continuous supply of leukocytes. Hematopoietic
stem and progenitor cells (HSPCs) play a major role in supplying
these peripheral immune cells. Various inflammatory cytokines
and interferons (IFNs) from immune or infected cells reportedly
induce both HSPC cycling and their homing to infectious sites
(King and Goodell, 2011). In addition to cytokines, pathogen-
associated molecular patterns (PAMPs), including lipopolysac-
charide (Nagai et al., 2006), directly stimulate HSPCs through
specific pathogen recognition receptors. However, the mecha-
nisms underlying HSPC activity following infectious stress in vivo
remain elusive. Bis-(30-50)-cyclic dimeric guanosine monophos-
phate (c-di-GMP) is a second messenger that is utilized ubiqui-
tously by prokaryotes and is associated with numerous bacterial
activities, including motility, biofilm formation, and pathogenesis
(Hengge, 2009). In addition to its role as a bacterial second
messenger, c-di-GMP was recently recognized as an immune-
stimulating molecule in mammalian cells (Karaolis et al., 2007).
The endoplasmic protein stimulator of IFN genes (STING, also
designated TMEM173) was originally identified as an adaptor
protein essential for the innate immune response against cyto-
solic DNA (Ishikawa and Barber, 2008; Zhong et al., 2008).
STING is also recognized as an endogenous c-di-GMP receptor,
sharing the same signaling pathway with the cytosolic DNA-
sensing mechanism (Burdette et al., 2011). Thus, it is essential
to determine whether the c-di-GMP/STING pathway functions
in host defense mechanisms against bacterial infection and, if
so, how that activity affects HSPCs.
In this study, we identify c-di-GMP as a signal-transducing
PAMP for HSPCs. We report that c-di-GMP alters HSPC kineticsCell Reports 11, 71–84, April 7, 2015 ª2015 The Authors 71
and dynamics through the STING pathway, promoting cell cycle
entry and expansion of multipotent progenitors (MPPs) aswell as
mobilization of HSPCs into the spleen. Furthermore, we show
that c-di-GMP modulates the bone marrow (BM) microenviron-
ment to induce HSPC mobilization. Overall, we propose that
c-di-GMP is a crucial regulator of HSPCs following bacterial
infection.
RESULTS
Bacterial Infection Decreases the Number of Long-Term
Hematopoietic Stem Cells
To determine how HSPCs respond to septicemia, we used a
murine cecal ligation and puncture (CeLP) model to induce
poly-microbial intraperitoneal infection (Rittirsch et al., 2009).
The number of white blood cells (WBCs) (especially granulo-
cytes) and platelets significantly decreased 48 hr after CeLP,
consistent with observations in mice with severe sepsis (Fig-
ure 1A). BM cellularity did not significantly decrease (Figure 1B),
but, as in peripheral blood (PB), the number of granulocytes
decreased while the number of monocytes increased (data not
shown). The number of Lin Sca-1+ c-Kit+ (LSK) cells increased
2-fold, while myeloid progenitors with the marker phenotype
Lin c-Kit+ Sca-1 (LKS) slightly decreased in number (Fig-
ure 1C). Although the frequency (Figure 1D) and number
(Figure 1E) of MPPs with the phenotypes CD150 and
CD150+CD48+ LSK expanded 48 hr after CeLP, cells in the highly
purified long-term hematopoietic stem cell (LT-HSC) fraction
with the marker phenotype CD150+CD41CD48 LSK (Fig-
ure 1E) or CD150+CD41CD48CD34Flt3 LSK (Figure 1F)
significantly decreased when compared with the sham-surgery
group. The CeLP group showed an activated cell-cycle status
in each HSPC fraction examined (Figure 1G).
To assess HSPC behavior following infectious stress, we sub-
jected mice to Salmonella infection, which induces septicemia,
and determined the HSPC number 5 days later (Figure S1A).
Similar to CeLP, the number of cells in the LSK fraction, espe-
cially MPPs, expanded (Figures S1B–S1D), whereas enriched
HSC fractions decreased (Figures S1D and S1E). These findings
support the idea that HSPCs directly respond to systemic bacte-
rial infection and that theMPP fraction expands at the expense of
the LT-HSC fraction.
c-di-GMP Administration Mimics Bacterial Infection
Toll-like receptor (TLR) signaling and type I IFN signaling are
dispensable for HSPC expansion in a CeLP model (Scumpia
et al., 2010); therefore, we speculated that other bacteria-spe-
cific molecules that circumvent conventional TLR signaling path-
waysmust target HSPCs to stimulate expansion. The c-di-GMP-
activated STING/Irf3 axis senses cytosolic DNA independent of
TLR signaling (Ishikawa and Barber, 2008; Zhong et al., 2008);
therefore, we focused on c-di-GMP as a candidate molecule
that could affect HSPC kinetics. To analyze an effect of c-di-
GMP on hematopoiesis in vivo, we administered c-di-GMP to
mice (Figure 2A). WBC counts, hemoglobin levels, and platelet
counts were transiently halved 3 days after c-di-GMP treatment
(Figure S2A). The number of bone marrow mononuclear cells
(BMMNCs) also decreased (Figure 2B). The frequency of lym-72 Cell Reports 11, 71–84, April 7, 2015 ª2015 The Authorsphocytes decreased, whereasmyeloid cells increased 3 days af-
ter c-di-GMP treatment (Figure S2B). However, the number of
cells in each differentiated fraction decreased upon c-di-GMP
treatment (Figure S2B). Thus, c-di-GMP treatment faithfully
mimics the conditions associated with transient pancytopenia
observed following severe sepsis, prolonged infection, and im-
mune dysregulation (King and Goodell, 2011).
c-di-GMP Alters HSPC Number and Function in the BM
We next examined the effect of c-di-GMP on immature hemato-
poietic fractions in the BM. c-di-GMP treatment induced a
striking reduction in the number and frequency of all these pro-
genitors in the BM (Figure S2C). c-di-GMP decreased the
HSC-enriched fraction in number and frequency (Figures 2C
and 2D). Analysis of the LSK fraction revealed that c-di-GMP
treatment upregulated Sca-1 expression in a manner similar to
that reported following IFN stimulation (Pietras et al., 2014) (Fig-
ure 2C), raising the possibility that Sca-1 progenitor fractions
contaminate the LT-HSC fraction. To minimize this possibility,
we examined dye efflux (Challen et al., 2010) (Figures 2E and
2F), activity of an Evi1-GFP reporter (which is specifically ex-
pressed in the LSK fraction; Kataoka et al., 2011) (Figures 2G
and 2H) and CD34 and Flt3 staining (Figures S2D and S2E).
The number of CD150+CD41CD48 LSK Evi1+ cells weakly
or not stained by Hoechst dye among HSPCs and
CD150+CD41CD48CD34Flt3 LSK cells decreased (Figures
2F, 2H, and S2E). Overall, the number of HSCs decreased
following c-di-GMP treatment.
Furthermore, upon bone marrow transplantation (BMT), c-di-
GMP-treated BM cells showed a reduced repopulation capacity
(Figure 2I), supporting the idea that the number of functional
HSCs decreases following c-di-GMP treatment, as reported for
HSPCs in a sepsis model (Burberry et al., 2014). However,
HSCs (CD150+CD41CD48CD34Flt3 LSK cells) purified
following c-di-GMP treatment showed a repopulation capacity
comparable to that of control cells, except for at 1 month after
BMT (Figure 2J), suggesting that anomalous HSC activity is
transient.
By contrast, in c-di-GMP-treated mice, the frequency and
number of MPPs, which give rise to all hematopoietic lineages
but have a limited self-renewal capacity, exceeded that seen in
control mice (Figures 2C and 2D). We also confirmed that the fre-
quency of MPPs, defined as CD34+Flt3+ LSK cells, increased
upon c-di-GMP treatment (Figure S2F). We next examined the
effect of c-di-GMP treatment on MPP function, as indicated by
short-term reconstitution and in vitro clonogenic capacity. Both
CD150+CD41/CD48+ LSK cells and CD34+Flt3+ LSK cells from
c-di-GMP-treated Ubc-GFP reporter mice, which ubiquitously
express GFP, showed reduced short-term reconstitution of
myeloid/lymphoid/erythroid/platelet cells (Figure 2K). In addi-
tion, colonies derived from single MPPs of c-di-GMP-treated
mice were primarily granulocytes and the number of cells per
colony was lower than that in controls and was similar to that
in the LKS fraction. By contrast, STING-deficient cells showed
a comparable colony-forming capacity in the presence or
absence of c-di-GMP (Figure S2G). This result does not exclude
the possibility that LKS cells contaminated the LSK fraction.
Given that LKS cells do not express Flt3, we conclude that
Figure 1. Polybacterial Infection Decreases the Number of LT-HSCs
(A–F) Mice underwent a sham operation (sham, open bars) or CeLP (closed bars) and were sacrificed 48 hr later (mean ± SD, n = 4). (A) Peripheral WBC counts,
hemoglobin levels (Hb), and platelet counts (Plt) were examined. (B) Analysis of BM cellularity. (C) The number of LSK cells and myeloid progenitors (LKS) from
sham (open bars) and CeLP (closed bars) groups (mean ± SD, n = 4). (D) Representative FACS plots of LSK-gated BM cells from sham and CeLP groups. CD150
and CD41/CD48 expression is shown. (E) The number of HSPCs in the LSK fraction from sham (open bars) and CeLP (closed bars) groups (mean ± SD, n = 4).
(F) The number of purified HSCs as determined by the marker phenotype CD150+CD41CD48CD34Flt3 LSK (mean ± SD, n = 4). SLAM LSK indicates the
marker phenotype CD150+CD41CD48 LSK.
(G) Cell-cycle status was analyzed 48 hr after sham or CeLP surgeries (mean ± SD, n = 3–4). The indicated HSPC fractions in the BM were analyzed by Hoechst
33342 and BrdU staining. The percentages of BrdU+ cells are shown.
See also Figure S1.following c-di-GMP treatment, the frequency of CD34+ Flt3+
MPP cells increased while their reconstitution potential in BM
decreased.
c-di-GMP Dampens the Cell-Cycle Quiescence,
ReconstitutionCapacity, andMetabolic Status of HSPCs
We next asked how c-di-GMP treatment altered HSC number
and function. We assessed the cell-cycle status of HSPCs using
short-term bromodeoxyuridine (BrdU) incorporation assays.c-di-GMP induced the proliferation of primitive HSCs, but not
of other HSPCs (Figure 2L). Metabolic analysis of HSPCs from
c-di-GMP-treatedmice revealed reduced intracellular ATP levels
and increased lactate dehydrogenase (LDH) activity (Figures
S2H and S2I) in STING+/+ HSCs and MPPs, which was not
seen in STING/ cells. Several glycolytic genes and tricarbox-
ylic acid (TCA) cycle-associated genes were also inversely regu-
lated in STING+/+ cells (Figure S2J). On the other hand, no signif-
icant increase in apoptotic cells was detected in the HSPCCell Reports 11, 71–84, April 7, 2015 ª2015 The Authors 73
Figure 2. c-di-GMP Administration Induces HSPC Proliferation and Attenuates Their Reconstitution Capacity
(A) Experimental design of in vivo c-di-GMP administration. Mice were intraperitoneally injected with PBS (open bars) or 200 nmol of c-di-GMP (closed bars), and
BM cells were analyzed 72 hr later.
(B) The total number of BMMNCs was halved after c-di-GMP treatment (mean ± SD, n = 10 from three independent experiments).
(C) Flow cytometric analysis of the BMHSPC fraction. Representative FACSplots of the Lin fraction and the frequency amongwhole BMcells are shown (mean ±
SD, n = 5 from two independent experiments).
(D) The number of cells in the LSK-gated fraction (mean ± SD, n = 5 from two independent experiments). The c-di-GMP-treated group showed a significant
decrease in the number of cells in the HSC fraction (CD150+CD41CD48LSK), whereas the number of cells in multipotent progenitor fractions (CD150+CD48+
and CD150CD48+LSK) increased.
(E) Flow cytometric analysis of the BM side population (SP). Representative FACS plots of the CD150+CD41CD48 (SLAM) LSK-gated SP fraction and the
frequency among whole BM cells are shown (mean ± SD, n = 4).
(F) The number of BM cells residing in the SP among the SLAM LSK-gated fraction (mean ± SD, n = 4).
(G) Gating strategy of Evi1+ cells using Evi1-GFP reporter mice. A representative histogram of the CD150+CD41CD48 (SLAM) LSK-gated fraction is shown.
Gray line, Evi1+/+ mouse; blue line, Evi1GFP/+ mouse treated with PBS; orange line, Evi1GFP/+ mouse treated with c-di-GMP.
(H) The number of Evi1-GFP+ CD150+CD41CD48 LSK cells in the BM from PBS- (Ctlr) or c-di-GMP (cdG)-treatedmice (mean ±SD, n = 4 from two independent
experiments).
(I) A competitive repopulation assay in which 43 105 BM cells from mice (Ly5.1) intraperitoneally injected with PBS (Ctrl) or 200 nmol of c-di-GMP (cdG) 3 days
before sacrifice were transplanted into lethally irradiated recipients (Ly5.2) together with 43 105 competitor BM cells (Ly5.2). Percentages of donor-derived cells
among PB cells of control (open boxes) or c-di-GMP-treated (closed boxes) mice at the indicated number of weeks after BMT are shown (mean ± SD, n = 6).
(J) A competitive repopulation assay in which 500 sorted LT-HSCs (CD150+CD41CD48CD34Flt3 LSK) frommice (Ly5.2) intraperitoneally injected with PBS
(Ctrl) or 200 nmol of c-di-GMP (cdG) 3 days before sacrifice were transplanted into lethally irradiated recipients (Ly5.1) together with 43 105 competitor BM cells
(Ly5.1). Percentages of donor-derived cells among PB cells of control (open boxes) or c-di-GMP-treated (closed boxes) groups at the indicated number of weeks
after BMT are shown (mean ± SD, n = 6; representative of three independent experiments).
(legend continued on next page)
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fraction, suggesting that the decreased HSPC number and fre-
quency is not attributable to the induction of apoptosis (Fig-
ure S2K). In agreement, expression levels of apoptosis-related
genes in purified HSCs were not significantly upregulated after
c-di-GMP treatment (Figure S2L). By contrast, expression
levels of cyclin-dependent kinase inhibitors were consistently
decreased in HSCs relative to controls after c-di-GMP treatment
(Figure 2M). Collectively, these findings indicate that c-di-GMP
treatment induces the entry of HSCs into the cell cycle rather
than apoptosis. Importantly, the endogenous STING ligand,
cGAMP (Ablasser et al., 2013), elicited HSPC responses less
potently than c-di-GMP (Figure S2M), suggesting a c-di-GMP-
specific role in anti-microbial defense systems other than
cGAS-mediated anti-double-stranded DNA responses.
c-di-GMP Induces HSPC Expansion in the Spleen
Given that c-di-GMP is potentially an immunostimulatory mole-
cule, we hypothesized that it activates HSPC egress from the
BM. We first performed histological observation of the spleen
with or without c-di-GMP treatment. As expected, we observed
spleen hematopoiesis marked by the presence of megakaryo-
cytes in the red pulp, with slight destruction of the white pulp ar-
chitecture (Figure 3A). There was a significant increase in spleen
weight (Figure S3A) and MPP frequency and number compared
with controls (Figures 3B and 3C; data not shown), while HSCs
and differentiated cells did not show a significant increase (Fig-
ures 3C–3E and S3B–S3D), indicating that c-di-GMP-induced
expansion is prominent in MPP fractions. Upon transplantation
of splenocytes into lethally irradiated mice, the control group
died by day 12, whereas 62.5% of mice transplanted with cells
from c-di-GMP-treated mice survived (Figure 3G), indicating
that functional HSPCs had been mobilized to the spleen. Intrigu-
ingly, however, the long-term reconstitution of purified HSCs did
not significantly differ between spleen cells from c-di-GMP-
treated and control groups (Figure S3D), in accordance with
the comparable number of HSCs between the two groups in
the spleen. Use of a larger sample size (n = 26) enabled us to
detect increases in splenic HSC number following c-di-GMP
treatment (Figure S3F). On the other hand, MPPs from c-di-
GMP-treated Ubc-GFP reporter mice showed enhanced short-
term reconstitution of PB cells, in sharp contrast to BM MPPs
(Figures 2K and 3G). The in vitro differentiation capacity of single
STING+/+ or STING/ MPPs did not markedly differ between
control and c-di-GMP-treated groups (Figure S3H).
The frequency (Figure S3G) and colony-forming capacity (Fig-
ures S3I and S3J) of HSPC fractions also increased in PB after
c-di-GMP treatment, suggesting that immature HSPCs are
mobilized to the periphery after c-di-GMP administration. How-
ever, BrdU analysis showed that CD150+CD41/CD48+ LSK cells
in the spleen robustly accumulated BrdU following c-di-GMP(K) Five hundred CD150+CD41/CD48+ LSK cells, CD34+Flt3+ LSK cells, or LKS c
mice were transplanted. The frequency of donor-derived cells was assessed 2 (u
(L) Cell-cycle status of the indicated HSPC fractions in the BM as measured b
CD150+CD41CD48 LSK cells specifically showed an activated cell-cycle statu
(M) Expression of cyclin-dependent kinase inhibitor transcripts (Cdkn1a, Cdkn1
mice intraperitoneally injected with PBS (Ctrl, open bars) or 200 nmol of c-di-GMP
normalized to b-actin expression and is expressed as the fold induction compar
*p < 0.05 and **p < 0.01 compared to PBS-injected control mice. See also Figurtreatment, suggesting that both migration and proliferation un-
derlie the increase in splenic MPPs (Figure S3K).
Of note, cGAMP did not sufficiently increase the number of
splenic HSPCs compared to c-di-GMP (Figure S3L).
c-di-GMP Activates the Irf3/Type I IFN Axis in LT-HSCs
through STING
We performed a cDNA microarray followed by gene set enrich-
ment analysis (GSEA) on purified LT-HSCs to examine which
pathway is activated following c-di-GMP treatment in vivo.
IFN-a response genes and Irf3 target genes were significantly
enriched in the c-di-GMP treatment group (Figure 4A). Using
real-time qPCR, we confirmed that both STING and Irf3 were
highly expressed in HSPC fractions, including LT-HSCs, at levels
comparable to or even higher than those in BM-derived macro-
phages (Figure 4B).
In STING/ mice, the numbers of HSCs and MPPs were un-
changed following c-di-GMP treatment (Figure 4C). In addition,
phenotypic HSPC expansion in the spleen was abrogated in
c-di-GMP-treated STING/ mice (Figure 4D). Thus, the effects
of c-di-GMP on HSPCs were entirely dependent upon STING-
mediated signaling. To evaluate the contribution of c-di-GMP/
STING-dependent signaling to an anti-microbial response, we
performed CeLP on STING/ mice. MPP expansion in the BM
was partially abolished in STING/ mice, while the numbers of
HSCs in the BM (Figure S4A) and HSPCs in the spleen (Fig-
ure S4B) were not restored. We also confirmed insufficient
MPP expansion in the BM of STING/ mice at day 3 of CeLP
(data not shown), indicating that STING-mediated signaling
acts primarily on MPP expansion in the BM under bacterial sep-
tic conditions.
The Irf3/Type I IFNAxisUnderlies HSPCExpansion in the
BM but Does Not Regulate HSPC Mobilization
Our findings indicate that STING is essential for c-di-GMP
signaling in HSPCs. Given that STING transduces its signal via
Irf3/type I IFN (Crane and Cao, 2014; Ishikawa and Barber,
2008), we treated IFN-a receptor 1 (Ifnar1)-deficient (Ifnar1/)
mice with c-di-GMP to determine if treatment stimulated HSPCs
in the absence of a type I IFN response. MPP expansion
observed in Ifnar1+/+ mice was at least partially inhibited in
Ifnar1/ mice (Figure 4E), while the decrease in HSC number
seen in Ifnar1+/+ mice was not rescued in Ifnar1/ mice. By
contrast, MPPs, which egressed to the spleen upon c-di-GMP
treatment in Ifnar1+/+ mice, were not reduced in number in the
spleen of Ifnar1/ mice. Surprisingly, phenotypic HSCs, which
did not expand in response to c-di-GMP in Ifnar1+/+ mice,
expanded in the absence of Ifnar1 (Figure 4F), suggesting that
type I IFN negatively regulates HSC mobilization in the presence
of c-di-GMP.ells from BMMPP fractions of PBS- (Ctrl) or c-di-GMP (cdG)-treated Ubc-GFP
pper panels) and 4 (lower panels) weeks later (n = 5).
y Hoechst 33342 and BrdU staining. Percentages of BrdU+ cells are shown.
s after c-di-GMP treatment (mean ± SD, n = 5).
b, Cdkn1c, and Cdkn2a) in CD150+ CD41CD48CD34Flt3 LSK cells from
(cdG, closed bars) 3 days before analysis (mean ± SEM, n = 4). Each value was
ed to control group levels.
e S2.
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Figure 3. c-di-GMP Induces the Expansion of Splenic HSPCs
(A) Mice were intraperitoneally injected with PBS (Ctrl) or 200 nmol of c-di-GMP (cdG), and the spleen was stained with H&E. Arrowheads indicate megakar-
yocytes. A high-magnification image is shown as an inset on the c-di-GMP image. Scale bars indicate 100 mm.
(B andC) Micewere injected intraperitoneally with 200 nmol of c-di-GMP (closed bars) or PBS (open bars), and the cell number of each indicated HSPC fraction in
the spleen was analyzed 3 days later. (B) Flow cytometric analysis of the splenic HSPC fraction. Representative FACS plots of the Lin fraction and the frequency
among whole splenocytes are shown (mean ± SD, n = 4). (C) The number of cells in the LSK fractions in the spleen. The number of MPPs (CD150+CD48+ LSK,
CD150CD48+ LSK, and CD34+Flt3+ LSK) increased significantly, while the number of LT-HSCs (CD150+CD48 LSK) was comparable to that in the control group
(mean ± SD, n = 4–10).
(D) The number of spleen cells residing in the SP of the SLAM LSK-gated fraction (mean ± SD, n = 4).
(E) The number of Evi1-GFP+CD150+CD41CD48 LSK cells in the spleen of PBS- (Ctrl) or c-di-GMP (cdG)-treatedmice (mean ±SD, n = 4 from two independent
experiments).
(F) Five hundred CD150+CD41/CD48+ LSK cells, CD34+Flt3+ LSK cells, or LKS cells from spleen MPP fractions of PBS- (Ctrl) or c-di-GMP (cdG)-treated Ubc-
GFP reporter mice were transplanted. The frequency of donor-derived cells was examined 2 (upper panels) and 4 (lower panels) weeks later (n = 5).
(G) Mice were injected intraperitoneally with PBS (Ctrl) or 200 nmol of c-di-GMP (cdG), and 53 105 spleen cells from each group were transplanted into lethally
irradiated (9.5 Gy) mice 3 days later. A Kaplan-Meier survival curve is shown (n = 8); the dashed line indicates the Ctrl group and the solid line indicates the cdG
group.
*p < 0.05, **p < 0.01, and ***p < 0.001 compared with control mice. ND, not detected. See also Figure S3.Aswas seen in Ifnar1/mice, the number of phenotypicMPPs
in theBMof Irf3/micedidnot increase in response toc-di-GMP
treatment, while the number of HSCs in the BMwas comparable
in c-di-GMP-treated Irf3+/+ and Irf3/mice (FigureS4C).Of note,76 Cell Reports 11, 71–84, April 7, 2015 ª2015 The Authorsnot onlyMPPs but also phenotypic HSCs expanded in the spleen
of c-di-GMP-treated Irf3/ mice (Figure S4D).
Irf7, another master regulator of type I IFN signaling (Honda
and Taniguchi, 2006), was expressed at comparable levels in
HSPCs and BM-derived macrophages (Figure S4E), and HSCs
exhibited a 4-fold increase in Irf7 expression following c-di-
GMP administration (Figure S4F). We tested the effects of c-di-
GMP in Irf3/Irf7 doubly deficient (Irf3/:Irf7/) mice. Similar to
observations in Ifnar1/ and Irf3/ mice, MPP expansion in
the BM was abrogated in Irf3/:Irf7/ mice following c-di-
GMP treatment (Figure S4G), whereas both phenotypic HSCs
and MPPs markedly expanded in the spleen (Figure S4H).
On the other hand, inhibition of NF-kB, another downstream
STING target, by the IKKa inhibitor Bay11-7082 almost
completely rescued the effects of c-di-GMP, suggesting that
NF-kB signaling downstream of c-di-GMP/STING is an impor-
tant regulator of HSPC behavior (Figures S4I and S4J). Notably,
however, c-Kit expression was decreased in c-di-GMP- or
Bay11-7082-treated mice (data not shown), making it difficult
to accurately determine the number of HSPCs.
STING Regulates HSPC Homeostasis in the BM
and Spleen in Both Cell-Autonomous and
Non-Cell-Autonomous Manners
Wenext askedwhether c-di-GMP treatment reduces the sizes of
various HSPC fractions (Figures 2C and 2D) directly or indirectly.
c-di-GMP is difficult to introduce into cultured cells without lipo-
fection in an ex vivo setting (McWhirter et al., 2009), and HSCs
are highly lipofection resistant (Keller et al., 1999); therefore,
we used the STING stimulant 10-carboxymethyl-9-acridanone
(CMA) (Cavlar et al., 2013), which can freely enter the cytoplasm,
to test whether STING stimulation altered HSPC proliferation. To
this end, we performed ex vivo colony-forming assays in the
presence or absence of CMA using STING+/+ or STING/
BMMNCs as well as LSK cells (Figure 5A). The colony-forming
capacity of both STING+/+ BMMNCs and LSK cells dose-depen-
dently decreased following CMA treatment, but STING/ cells
did not exhibit a decrease in CFU in culture (CFU-C) following
CMA treatment (Figure 5B). Additionally, the number of high pro-
liferative potential colony-forming cells (HPP-CFCs) dose-
dependently decreased following CMA treatment, an effect
that was absent in STING/ cells (Figure 5C). Unexpectedly,
ex vivo treatment of BMMNCs, LSK cells, or LT-HSCs with
c-di-GMP also led to dose-dependent decreases in both CFU-
Cs and HPP-CFCs (Figures S5A and S5B). This phenotype
was also observed in STING/ HSCs at higher concentrations
(100 mM) (Figures S5C and S5D), suggesting that c-di-GMPplays
an unknown STING-independent role in this context, which was
not observed in vivo (Figure 4B). To confirm the effects of STING-
mediated signaling on LT-HSC reconstitution capacity, we incu-
bated sorted STING+/+ or STING/ HSCs in culture medium
containing CMA for 3 days and then assessed the HSC number.
Unlike in comparably treated STING/ cells, the number of
HSCs significantly decreased among CMA-treated STING+/+
cells (Figure 5D), again revealing an HSPC-autonomous function
of STING-mediated signaling. We also treated STING+/+ and
STING/ HSCs with CMA for 3 days and then transplanted
the cells into recipients (Figure 5E). Short-term reconstitution
of CMA-treated STING+/+ cells was abrogated, whereas that of
STING/ cells was not, consistent with the transiently
decreased repopulation capacity seen after in vivo c-di-GMP
treatment (Figure 2). On the other hand, 16 hr of CMA treatmentdid not compromise the HSC repopulation capacity (Figures S5E
and S5F), suggesting that short-term exposure is not sufficient to
elicit downstream STING signaling in HSCs.
Finally, to test a direct effect of c-di-GMP/STING signaling on
HSPCs in vivo, we performed reciprocal transplantations, in
which the BMofSTING+/+ recipients was replacedwithSTING+/+
or STING/ donor cells (Figures 5F–5H) and the BM of STING+/+
or STING/ recipients was replaced with STING+/+ donor cells
(Figures 5I–5K). In agreement with the results of CMA experi-
ments, the number of STING/ donor HSCs in STING+/+ recip-
ients did not decrease following c-di-GMP administration (Fig-
ure 5G) and splenic MPPs did not increase (Figure 5H),
suggesting a cell-autonomous effect of c-di-GMP on HSPCs.
Likewise, the number of STING+/+ donor HSCs in STING/ re-
cipients did not decrease (Figure 5J) and HSPC expansion in
the spleen was abrogated following c-di-GMP treatment (Fig-
ure 5K). Collectively, in addition to cell-autonomous activity,
STING controls the HSPC pool size in the BM and spleen in a
non-cell-autonomous manner. To further test the cell-autono-
mous effects of c-di-GMP on HSPCs, we established chimeric
mice whose BM contained a 1:1 ratio of STING+/+ and
STING/ cells and treated them with c-di-GMP (Figure S5G).
Following treatment, BM chimerism of STING/ donor-derived
myeloid and B cells was decreased, suggesting that, in addition
to its direct impairment of HSC function, the cell-autonomous
and non-cell-autonomous effects of c-di-GMP treatment favor
myeloid andB cell production, presumably through themigration
of MPP cells to the periphery (Figure S5H).
c-di-GMP Attenuates the Niche Function
of Mesenchymal Stromal Cells in BM
We next sought to define the mechanisms underlying HSPC
egress from the BM. HSCs reside in specialized BM niches
that regulate the balance between self-renewal and differentia-
tion, and the ablation of niche cells promotes loss of quiescence
and HSC mobilization (Me´ndez-Ferrer et al., 2010), effects com-
parable to those observed following c-di-GMP administration.
BM architecture was drastically changed by c-di-GMP treat-
ment, with a massive decrease in cellularity and an increase in
the size of the sinusoidal area surrounded by PLVAP+ endothelial
cells (Figures 6A–6C). This change in sinusoidal architecture
was also observed in Ifnar1/ mice, Irf3/:Irf7/ mice, and
STING/ BM chimeric mice, whereas STING/ mice showed
no structural changes (Figure S6A), suggesting a STING-depen-
dent Ifnar1/Irf3/Irf7-independent effect of c-di-GMP on non-he-
matopoietic cells. These changes motivated us to examine the
frequency and number of several types of HSPC niche cells
that reportedly reside in the BM, including endothelial cells, oste-
oblastic progenitor cells, andmesenchymal stromal cells (MSCs)
(Pinho et al., 2013), which essentially overlap with CXCL12-
abundant reticular cells (Omatsu et al., 2010) and
CD45Ter119LepR+ cells (Zhou et al., 2014). Every non-he-
matopoietic niche cell type showed a significant decrease in
both frequency and number after c-di-GMP treatment (Figures
6D and 6E), suggesting that deformation of multiple niche com-
ponents promotes HSPC detachment from the BM.
Among BM non-hematopoietic cells, platelet-derived
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Figure 4. Type I IFN Activity Is Partially Responsible for HSPC Expansion but Inhibitory to Phenotypic HSPC Expansion in the Spleen
(A) GSEA was performed using cDNA microarray data of CD150+CD41CD48CD34Flt3 LSK cells from PBS- or c-di-GMP-treated mice. Results for an Irf3
downstream target gene set and an IFN-a responsive gene set are shown. FDR-q, false discovery rate. NES, normalized enrichment score.
(B) Expression levels of STING (left) and Irf3 (right) in the indicated hematopoietic fractions, including LT-HSCs (CD34Flt3 LSK, LT), short-term HSCs
(CD34+Flt3 LSK, ST), multipotent progenitors (CD34+Flt3+ LSK, MPP), myeloid progenitors (Lineagec-Kit+Sca-1, MP), lineage-marker-positive cells (Lin+),
granulocytes (Gr-1+Mac-1+, Gr), monocytes (Gr-1Mac-1+, mono), and BM-derivedmacrophages (Mac), were analyzed by qPCR. Each value was normalized to
b-actin expression and is expressed as the fold difference compared to levels in LT-HSC samples (mean ± SD, n = 4).
(legend continued on next page)
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expressed the highest levels of STING and Irf3 (Figure 6F), sug-
gesting that, in addition to hematopoietic cells, MSCs are a pri-
mary target of STING-mediated signaling, and that the
decrease in the number of other cell types could be ascribed
to non-cell-autonomous mechanisms. We then quantified the
expression levels of specific factors that maintain HSC function
or anchor cells to the niche in sorted niche cells upon c-di-
GMP treatment. KitL, CXCL12, Angpt1, and VCAM1 expres-
sion levels invariably decreased following the treatment of
MSCs (Figure 6G). Importantly, MSC expression of factors
that maintain HSPCs was lower in c-di-GMP-treated Ifnar1/
mice than in similarly treated controls (Figure 6G). This result
indicates that c-di-GMP treatment attenuates HSPC mainte-
nance and anchoring in the BM niche and that the underlying
mechanism is type I IFN independent. HSCs co-cultured with
CMA-treated OP9 cells showed a dose-dependent decrease
in colony number, confirming a negative effect on niche func-
tion (Figure S6B).
We also asked whether the splenic niche, where mobilized
HSPCs colonize, is altered in response to c-di-GMP. Indeed,
although the microscopic architecture of the splenic niche was
not deformed following c-di-GMP administration (Figure S6C),
the number of non-hematopoietic cells significantly increased
in the spleen (Figures S6D and S6E).
Signaling via TGF-b and G-CSF Is Essential for
c-di-GMP-Dependent HSPC Expansion in the Spleen
To define the downstream targets of c-di-GMP, we performed
GSEA of cDNAmicroarray data obtained from c-di-GMP-treated
or non-treated MSCs. TGF-b signaling, as well as type I IFN, NF-
kB, p38MAPK, and fibroblast growth factor (FGF) signaling, was
upregulated (Figures 7A and S7A). In addition, phosphorylation
of ERK1/2 and AKT, which are downstream targets of FGF,
was not altered in MSCs after c-di-GMP treatment (Figure S7C).
Thus, we tested the effect of TGF-b signaling on HSPCs by c-di-
GMP. TGF-b promotes osteoblastic differentiation through
phosphorylation of Smad2 and Smad3 (Chen et al., 2012).
Accordingly, mRNAs encoding osteoblastic transcription factors
were invariably upregulated in c-di-GMP-treated MSCs,
whereas adipogenesis-related genes were downregulated (Fig-
ures 7B and S7B).
Smad2 exhibited focal activation in steady-state conditions
as previously reported (Brenet et al., 2013), while phospho-
Smad2 was globally upregulated after c-di-GMP treatment
(Figures 7C and 7D), an effect observed in Ifnar1/ and
Irf3/:Irf7/ mice (Figure S7D). Although TGF-b alone was
not sufficient to alter HSPC dynamics in the BM and spleen
(Figures S7E–S7G), TGF-b receptor 1 inhibition decreased
MPPs in the spleen upon c-di-GMP treatment, albeit with
no obvious change in BM HSPCs (Figures 7E–7G). We(C and D) STING+/+ (WT) or STING/ (KO) mice were intraperitoneally injected w
FACS 3 days later (mean ± SD, n = 4 from two independent experiments). (C) The
the LSK-gated fraction of the spleen.
(E and F) Ifnar1+/+ (WT) or Ifnar1/ (KO) mice were intraperitoneally injected with P
3 days later. (E) The number of cells in the LSK-gated fraction of the BM (mean ±
LSK-gated fraction of the spleen (mean ± SD, n = 5–8 from three independent e
*p < 0.05, **p < 0.01, and ***p < 0.001. n.s., not significant. See also Figure S4.conclude that TGF-b signaling is essential for HSPC expan-
sion in the spleen but does not alter the HSPC pool size in
the BM.
We next sought to identify cytokines that stimulate BM
HSPC function. Serum levels of G-CSF were increased in
c-di-GMP-treated mice, whereas levels of other inflammatory
cytokines were not (Figure S7H). Accordingly, c-di-GMP treat-
ment reduced HSPC mobilization in G-CSF receptor-deficient
mice (Csf3r/), whereas HSPC fractions in BM did not show
similar effects (Figures S7I and S7J), suggesting that G-CSF
is a c-di-GMP target. However, Smad2 phosphorylation was
observed in Csf3r/ mice (Figure S7D), suggesting that
G-CSF and TGF-b independently regulate HSPC expansion in
the spleen.
DISCUSSION
In this study, we identified crucial roles for c-di-GMP/STING
signaling in the dynamics of hematopoiesis through modulation
of HSPCs and their niches. A previous observation that HPSC
expansion under infectious stress occurs even in the absence
of TLR signaling or type I IFN responses indicated that
unknown bacteria-derived factors activate a signal that stimu-
lates HSPC expansion (Scumpia et al., 2010). Our results sug-
gest that c-di-GMP is a bacteria-derived activator of this
expansion that acts via the induction of extramedullary hema-
topoiesis and modulation of the BM microenvironment through
STING.
c-di-GMP/STING Signaling Induces MPP Expansion in
the Periphery and Decreases the Number of LT-HSCs
c-di-GMP treatment decreased the number of various hemato-
poietic cells, including LT-HSCs, in vivo. Notably, c-di-GMP
suppressed the reconstitution capacity and cell-cycle quies-
cence of LT-HSCs, whereas it substantially increased the
MPP number in the spleen, an effect likely due to the mobiliza-
tion and proliferation of MPPs. Although we could not calculate
the precise number of MPPs in the BM due to potential
contamination by the LKS fraction, as it has been reported
that the LKS fraction can contaminate MPPs in BM for IFN-
stimulated HSPCs (Pietras et al., 2014), the short-term reconsti-
tution capacity was potentiated in splenic MPPs. This finding
supports the idea that splenic HPSCs function to supply im-
mune cells in peripheral tissues through cell division (Massberg
et al., 2007).
In contrast to c-di-GMP treatment, the number of HSPCs in
STING/ mice subjected to CeLP was comparable to that in
STING+/+ mice, suggesting redundancy of signals downstream
of STING and those activated by bacteria via Toll-like or NOD1
receptors (Burberry et al., 2014).ith PBS (Ctrl) or 200 nmol of c-di-GMP (cdG), and BM cells were analyzed by
number of cells in the LSK-gated fraction of the BM. (D) The number of cells in
BS (Ctrl) or 200 nmol of c-di-GMP (cdG), and BM cells were analyzed by FACS
SD, n = 3–6 from two independent experiments). (F) The number of cells in the
xperiments).
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Figure 5. STING Regulates HSPC Homeostasis in the BM and Spleen in Both Cell-Autonomous and Non-Cell-Autonomous Manners
(A) CFU-Cs of 1 3 104 BMMNCs or 150 LSK cells from STING+/+ or STING/ mice at the indicated CMA concentrations (mean ± SD, n = 3).
(B) HPP-CFCs of BMMNC or LSK cells from STING+/+ or STING/ mice at the indicated CMA concentrations (mean ± SD, n = 3).
(C) Experimental design for the repopulation assay of CMA-treated HSCs. In total, 500 (for transplantation) or 2,000 (for flow cytometry) CD34Flt3 LSK cells
from STING+/+ or STING/ mice were treated with DMSO or 1 mM CMA for 3 days and analyzed by FACS or transplanted into lethally irradiated mice.
(D) The number of CD150+CD41CD48 LSK cells after 3 days of culture (mean ± SD, n = 5–6).
(E) The frequency of donor-derived cells 1 month after BMT (mean ± SD, n = 5–6).
(F) Experimental design for analysis shown in (G) and (H). Ly5.2+ STING+/+ (WT) or STING/ (KO) donor cells were transplanted into Ly5.1+ STING+/+ recipient
mice. Two months after BMT, mice were treated with PBS (Ctrl) or c-di-GMP (cdG), and the BM and spleen were analyzed 3 days later.
(G) The frequency of Ly5.2+ cells in the LSK-gated fraction of the BM (mean ± SD, n = 4).
(H) The frequency of Ly5.2+ cells in the LSK-gated fraction of the spleen (mean ± SD, n = 4).
(I) Experimental design for analysis shown in (J) and (K). Ly5.1+ STING+/+ BM cells were transplanted into Ly5.2+ STING+/+ (WT) or STING/ (KO) recipients. Two
months later, mice were treated with PBS (Ctrl) or c-di-GMP (cdG), and the BM and spleen were analyzed 3 days later.
(J) The number of LSK-gated cells in each indicated fraction of the BM (mean ± SD, n = 4).
(K) The number of LSK-gated cells in each indicated fraction of the spleen (mean ± SD, n = 4).
*p < 0.05, **p < 0.01, and ***p < 0.001. n.s., not significant. See also Figure S5.The Irf3/Type I IFN Axis Is a Bidirectional Regulator
of HSPCs
Type I IFN signaling is a major downstream target of STING
and an important response to infection that allows expansion
of the HSPC pool size (Essers et al., 2009; Sato et al., 2009).
In HSPCs, cell-cycle activation and mobilization are corre-
lated to some extent (Tesio et al., 2013). Unexpectedly, how-80 Cell Reports 11, 71–84, April 7, 2015 ª2015 The Authorsever, we demonstrated that Irf3/type I IFN signaling inhibits
phenotypic HSPC expansion in the spleen, suggesting that
cell mobilization and proliferation are independently regulated
in HSPCs, contrary to previous views. The literature suggests
that both cell-autonomous and non-cell-autonomous mecha-
nisms negatively regulate HSPCs. For example, type I IFN
signaling reportedly suppresses HSC activation ex vivo
Figure 6. c-di-GMP Attenuates MSC Function in the BM Niche
(A) Mice were intraperitoneally injected with PBS (Ctrl) or 200 nmol of c-di-GMP (cdG). The femur was fixed 3 days later and stained with H&E. Scale bars indicate
100 mm.
(B and C) Frozen sections of femur were stained with an anti-PLVAP monoclonal antibody (Meca32) and DAPI (nuclei). (B) Representative photomicrographs of
femur sections. Scale bars indicate 100 mm. (C) The proportion of the sinusoidal area in comparison to the entire BM area (mean ± SD, n = 5–8; representative of
three independent experiments).
(D and E) Mice were intraperitoneally injected with PBS (Ctrl, open bars) or 200 nmol of c-di-GMP (cdG, closed bars), and each indicated type of non-he-
matopoietic cells in the BM plug was analyzed 3 days later (mean ± SD, n = 5). (D) Representative FACS plots of non-hematopoietic cells and the frequency
among whole BM cells. (E) The number of cells in the indicated fractions.
(legend continued on next page)
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Figure 7. c-di-GMP-Dependent TGF-b Signaling Underlies Phenotypic HSPC Expansion in the Spleen
(A and B) GSEAwas performed using cDNAmicroarray data of MSCs (CD45Ter-119CD31PDGFRa+CD51+ cells) from PBS- or c-di-GMP-treated mice. FDR-
q, false discovery rate. NES, normalized enrichment score. (A) Results for gene sets of the TGF-b signaling pathway. (B) Results for gene sets of osteoblastic
transcription factors and adipogenesis-related genes.
(C and D) Immunohistochemical analysis of phospho-Smad2 in the BM upon c-di-GMP treatment. PBS (Ctrl) or 200 nmol of c-di-GMP (cdG) was intraperitoneally
administered and BM sections were stained with anti-leptin receptor (LepR), anti-PLVAP (Meca32), and anti-Smad2 phospho-specific (pSmad2) antibodies.
(C) Lower-magnification images. Scale bar indicates 50 mm. (D) Higher-magnification image of the area around a sinusoid. Arrowheads indicate LepR+/pSmad2+
cells. Scale bar indicates 20 mm.
(E) Experimental design of TGF-b inhibition. PBS (Ctrl) or 200 nmol of c-di-GMP (cdG) was intraperitoneally administered, followed by daily administration of
DMSO or 0.5 mg of Ly364947 for 3 days (n = 3–4, mean ± SD).
(F) The number of cells in the LSK fraction of the BM.
(G) The number of cells in the LSK fraction of the spleen.
*p < 0.05, **p < 0.01, and ***p < 0.001. n.s., not significant. See also Figure S7.(Pietras et al., 2014; Verma et al., 2002), an activity that re-
quires p38 MAPK activation in part. Another possible mecha-
nism is upregulation of a systemic inflammatory response. Irf3
reportedly interferes with expression of the p40 subunit of
interleukin (IL)-12, thereby limiting T helper type 1 cell (TH1)(F) Expression levels of STING (left) and Irf3 (right) in the indicated non-hematop
(G) The fold differences in expression levels (by qPCR analysis) of the indicated
compared to PBS-treated Ifnar1+/+ (WT) or Ifnar1/ (KO) mice (mean ± SD, n =
*p < 0.05, **p < 0.01, and ***p < 0.001. n.s., not significant. See also Figure S6.
82 Cell Reports 11, 71–84, April 7, 2015 ª2015 The Authorsand IL-17-producing helper T cell (TH17) activation upon viral
infection (Negishi et al., 2012). Thus, in turn, c-di-GMP treat-
ment may have augmented a systemic inflammatory response
in Irf3/, Irf3/:Irf/, and Ifnar1/ mice (Sato et al.,
2009).oietic fractions (mean ± SD, n = 4).
genes in MSCs (CD45Ter-119CD31PDGFRa+CD51+ cells) in c-di-GMP-
4).
c-di-GMP/STING Signaling Modulates Hematopoietic
Niches
Although previous studies have focused primarily on the effect of
inflammatory signals on HSPCs themselves (King and Goodell,
2011), our observations suggest the importance of niche cells
in response to infectious stress. HSPCs are mobilized to infec-
tion sites (Massberg et al., 2007); therefore, facilitating their
egress from the BM by niche modification is a reasonable de-
fense mechanism against infection. Others have proposed that
egress is induced by the degradation of CXCR4 in HSPCs and
CXCL12 in niche cells (Le´vesque et al., 2003). CD8+ T cells
were recently shown to play a role in HSPC stimulation by
promoting cytokine release from MSCs (Schu¨rch et al., 2014).
However, this mechanism cannot account for the c-di-GMP-
mediated response, because BM chimeras with STING/ he-
matopoietic cells and STING+/+ niche cells still show MPP
expansion in the BM and CD34+Flt3+ LSK cell expansion in the
spleen. MSCs show the highest STING expression among niche
cells; therefore, we propose that c-di-GMP has detrimental ef-
fects on the ability of MSCs to control HSC number and maintain
their function, likely through upregulating TGF-b signaling, as
discussed below. Loss of HSPC niche factors in the BM is
required for egress of these cells from the BM sinusoidal network
and to promote an inter-BM exchange of HSPCs, as well as to
supply immune cells to the periphery.
TGF-b Signaling Is Essential for MPP Expansion in the
Spleen by c-di-GMP/STING Signaling
TGF-bmaintains HSC function in a steady state (Yamazaki et al.,
2011) and facilitates restoration of HSC quiescence under stress
conditions (Brenet et al., 2013). We demonstrated that TGF-b
activation is also required for HSPC expansion in the spleen
following c-di-GMP treatment, an effect presumably due to
altered MSC function.
TGF-b treatment alone had a minimal mobilizing effect on
HSPCs compared with activation of type I IFN, NF-kB, or p38
MAPK, downregulation of Notch activity, or G-CSF overproduc-
tion. Nonetheless, TGF-b activity may cooperate with these fac-
tors to alter HSPC number and/or function through c-di-GMP-
STING signaling. Given the global upregulation of TGF-b in the
BM following c-di-GMP treatment independent of G-CSF
signaling, we do not exclude the possibility that TGF-b activates
a mechanism intrinsic to HSPCs that promotes their mobiliza-
tion, although gene expression profile data do not support this
conclusion.
This study reports how the bacteria-derived molecule c-di-
GMP governs HSPC dynamics following infection independent
of TLR and IFN signaling. c-di-GMP/STING signaling activates
various pathways in multiple cell types, including type I IFN
signaling and alteration of MSC function, to efficiently expand
and relocalize hematopoietic precursors, which would modulate
a robust response of HSPCs to bacterial infection. c-di-GMP
promotes cell-cycle entry and HSC mobilization; therefore, a
c-di-GMP mimetic or STING agonist could act as a novel
HSPCmodulator. Further investigation of the activity and regula-
tion of c-di-GMP and its downstream signals should benefit our
understanding of the relationship between the pathophysiology
of bacterial infection and HSPC dynamics.EXPERIMENTAL PROCEDURES
Mice
C57BL/6J mice (8–12 weeks old) were used in all experiments, unless other-
wise stated. C57BL/6-Ly5.1 congenic mice were used for competitive repopu-
lation assays. Irf3-deficient mice and Irf3/Irf7-deficient mice (Honda et al.,
2005) were kindly provided by Dr. Tadatsugu Taniguchi (University of Tokyo).
STING-deficient mice (Ishikawa and Barber, 2008) were kindly provided by
Dr. Takashi Saito (RIKEN) with the permission of Dr. Glen Barber (University
of Miami). IFNAR1-deficient mice (Mu¨ller et al., 1994) were purchased from
The Jackson Laboratory. Evi1-GFP reporter mice (Kataoka et al., 2011) were
provided by Dr. Mineo Kurokawa (University of Tokyo). Ubc-GFP reporter
mice (Schaefer et al., 2001) were purchased from The Jackson Laboratory.
CSF3R-deficient mice (Liu et al., 1996) were provided by Dr. Shinsuke Yuasa
(Keio University). All procedures were performed in accordancewith the guide-
lines of Keio University School of Medicine. For detailed methods, see Supple-
mental Experimental Procedures.
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